MassachusettsPrevention Quality Measures Compared to Achievable Benchmarks

The NHQDR quality measures specific to Prevention are compared to achievable benchmarks, which are derived from the top-performing States. Better performance of a State can mean higher or lower values of a measure, depending on the desired outcome. For example, low values are desirable for measures such as infant mortality, whereas high values are desirable for measures such as preventative screening. The categories of achievement have been standardized across the measure definitions so that:

 
Far away from benchmark - a State's value for a measure has not achieved 50% of the benchmark.
 
Close to benchmark - a State's value for a measure is between 50% and 90% of a benchmark (i.e., worse than the benchmark but has achieved at least half of the benchmark but not as much as 90% of a benchmark).
 
Achieved benchmark or better - a State's value for a measure is no worse than 90% of the benchmark value, the measure has achieved the benchmark. This category also includes the case in which the measure’s value is equal to or better than the benchmark.
Measures That Achieved Benchmark or Better
Measure Estimate Benchmark Distance to Benchmark
Cervical cancer diagnosed at advanced stage (all invasive tumors) per 100,000 women age 20 and over 7.2 7.6 Achieved: 5% better
Children ages 19-35 months who received 4 or more doses of diphtheria-tetanus-pertussis vaccine 94.0 90.6 Achieved: 4% better
Children ages 19-35 months who received 3 or more doses of polio vaccine 99.6 97.3 Achieved: 2% better
Children ages 19-35 months who received 1 or more doses of measles-mumps-rubella vaccine 98.6 96.4 Achieved: 2% better
Adolescents ages 13-15 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years 96.5 95.2 Achieved: 1% better
Children ages 19-35 months who received 1 or more doses of varicella vaccine 97.0 95.7 Achieved: 1% better
Adolescents ages 16-17 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years 97.0 95.9 Achieved: 1% better
Children ages 19-35 months who received 3 or more doses of hepatitis B vaccine 96.8 96.4 -0.5%
Adults who received a blood cholesterol measurement in the last 5 years 82.2 82.3 0.1%
Short-stay nursing home patients who had flu vaccination appropriately given 90.0 92.9 3.1%
Long-stay nursing home residents who were assessed for pneumococcal vaccination 93.9 98.0 4.2%
Long-stay nursing home patients who were assessed and appropriately given the seasonal influenza vaccine 90.0 94.1 4.4%
Short-stay nursing home residents who were assessed for pneumococcal vaccination 90.9 95.3 4.6%
Adolescents ages 13-15 who received 1 or more doses of meningococcal conjugate vaccine 90.3 95.4 5.4%
Adolescents ages 16-17 who received 1 or more doses of meningococcal conjugate vaccine 90.6 96.2 5.8%
Adults age 65 and over who ever received pneumococcal vaccination 73.9 78.7 6.1%
Home health patients who had influenza vaccination during flu season 78.9 84.8 7.0%
Breast cancer diagnosed at advanced stage (regional, distant stage, or local stage with tumor greater than 2 cm) per 100,000 women age 40 and over 77.9 72.8 7.0%
Adults ages 18-64 at high risk (e.g., COPD) who received an influenza vaccination in the last flu season 43.7 47.8 8.5%
Measures That Are Close to Benchmark
Measure Estimate Benchmark Distance to Benchmark
Adults age 65 and over who received an influenza vaccination in the last flu season 61.2 70.3 13.0%
Adults ages 18-64 at high risk (e.g., COPD) who ever received pneumococcal vaccination 38.3 44.8 14.5%
Home health patients who had pneumococcal polysaccharide vaccination 72.5 86.1 15.8%
Colorectal cancer diagnosed at advanced stage (tumors diagnosed at regional or distant stage) per 100,000 population age 50 and over 57.0 47.2 20.9%
Adolescent males ages 13-15 who received 3 or more doses of human papillomavirus (HPV) vaccine 32.9 43.2 23.9%
Measures With No Available Benchmark Information or Supplemental Measures
Measure Estimate Benchmark Distance to Benchmark
Composite measure: Children ages 19-35 months who received all recommended vaccines 85.3
Adolescents ages 16-17 years (excluding adolescents who have had varicella) vaccinated with at least 2 doses of varicella 98.7
Adolescent aged 13-15 years who received 3 or more doses of human papillomavirus (HPV) vaccine 40.0
Adolescent ages 16-17 years who received 3 or more doses of human papillomavirus (HPV) vaccine 63.2
Adolescents ages 13-15 years (excluding adolescents who have had varicella) vaccinated with at least 2 doses of varicella 96.2